Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1999;8(6):287–294. doi: 10.1080/09629359990298

The induction of cyclooxygenase-2 in IL-1beta-treated endothelial cells is inhibited by prostaglandin E2 through cAMP.

P Akarasereenont 1, K Techatrisak 1, S Chotewuttakorn 1, A Thaworn 1
PMCID: PMC1781816  PMID: 10815617

Abstract

Prostaglandins (PGs) have numerous cardiovascular and inflammatory effects. Cyclooxygenase (COX), which exists as COX-1 and COX-2 isoforms, is the first enzyme in the pathway in which arachidonic acid is converted to PGs. Prostaglandin E2 (PGE2) exerts a variety of biological activities for the maintenance of local homeostasis in the body. Elucidation of PGE2 involvement in the signalling molecules such as COX could lead to potential therapeutic interventions. Here, we have investigated the effects of PGE2 on the induction of COX-2 in human umbilical vein endothelial cells (HUVEC) treated with interleukin-1beta (IL-1beta 1 ng/ml). COX activity was measured by the production of 6-keto-PGF1alpha, PGE2, PGF2alpha and thromboxane B2 (TXB2) in the presence of exogenous arachidonic acids (10 microM for 10 min) using enzyme immunoassay (EIA). COX-1 and COX-2 protein was measured by immunoblotting using specific antibody. Untreated HUVEC contained only COX-1 protein while IL-1beta treated HUVEC contained COX-1 and COX-2 protein. PGE2 (3 microM for 24h) did not affect on COX activity and protein in untreated HUVEC. Interestingly, PGE2 (3 microM for 24h) can inhibit COX-2 protein, but not COX-1 protein, expressed in HUVEC treated with IL-1beta. This inhibition was reversed by coincubation with forskolin (100 microM). The increased COX activity in HUVEC treated with IL-1beta was also inhibited by PGE2 (0.03, 0.3 and 3 microM for 24h) in a dose-dependent manner. Similarly, forskolin (10, 50 or 100 microM) can also reverse the inhibition of PGE2 on increased COX activity in IL-1beta treated HUVEC. The results suggested that (i) PGE2 can initiate negative feedback regulation in the induction of COX-2 elicited by IL-1beta in endothelial cells, (ii) the inhibition of PGE2 on COX-2 protein and activity in IL-1beta treated HUVEC is mediated by cAMP and (iii) the therapeutic use of PGE2 in the condition which COX-2 has been involved may have different roles.

Full Text

The Full Text of this article is available as a PDF (252.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akarasereenont P., Bakhle Y. S., Thiemermann C., Vane J. R. Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide. Br J Pharmacol. 1995 Jun;115(3):401–408. doi: 10.1111/j.1476-5381.1995.tb16347.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akarasereenont P., Hide E., Ney P., Thiemermann C., Vane J. R. The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1. Agents Actions Suppl. 1995;45:59–64. doi: 10.1007/978-3-0348-7346-8_9. [DOI] [PubMed] [Google Scholar]
  3. Akarasereenont P., Mitchell J. A., Appleton I., Thiemermann C., Vane J. R. Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells. Br J Pharmacol. 1994 Dec;113(4):1522–1528. doi: 10.1111/j.1476-5381.1994.tb17169.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Akarasereenont P., Mitchell J. A., Bakhle Y. S., Thiemermann C., Vane J. R. Comparison of the induction of cyclooxygenase and nitric oxide synthase by endotoxin in endothelial cells and macrophages. Eur J Pharmacol. 1995 Jan 24;273(1-2):121–128. doi: 10.1016/0014-2999(94)00680-6. [DOI] [PubMed] [Google Scholar]
  5. Altstaedt H. O., Berzewski B., Breddin H. K., Brockhaus W., Bruhn H. D., Cachovan M., Diehm C., Dörrler J., Franke C. S., Gruss J. D. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids. 1993 Aug;49(2):573–578. doi: 10.1016/0952-3278(93)90163-q. [DOI] [PubMed] [Google Scholar]
  6. Ares J. J., Outt P. E. Gastroprotective agents for the prevention of NSAID-induced gastropathy. Curr Pharm Des. 1998 Feb;4(1):17–36. [PubMed] [Google Scholar]
  7. Becker A. J., Stief C. G., Schultheiss D., Truss M. C., Jonas U. Pharmakologische Therapie der erektilen Dysfunktion. Urologe A. 1998 Sep;37(5):503–508. doi: 10.1007/s001200050209. [DOI] [PubMed] [Google Scholar]
  8. Brown N. L., Alvi S. A., Elder M. G., Bennett P. R., Sullivan M. H. Interleukin-1beta and bacterial endotoxin change the metabolism of prostaglandins E2 and F2alpha in intact term fetal membranes. Placenta. 1998 Nov;19(8):625–630. doi: 10.1016/s0143-4004(98)90024-8. [DOI] [PubMed] [Google Scholar]
  9. Cabezas E. Medical versus surgical abortion. Int J Gynaecol Obstet. 1998 Dec;63 (Suppl 1):S141–S146. doi: 10.1016/s0020-7292(98)00196-9. [DOI] [PubMed] [Google Scholar]
  10. Fedyk E. R., Phipps R. P. Prostaglandin E2 receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10978–10983. doi: 10.1073/pnas.93.20.10978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ichikawa A., Sugimoto Y., Negishi M. Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Mediat Cell Signal. 1996 Sep;14(1-3):83–87. doi: 10.1016/0929-7855(96)00512-3. [DOI] [PubMed] [Google Scholar]
  12. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lee S. H., Soyoola E., Chanmugam P., Hart S., Sun W., Zhong H., Liou S., Simmons D., Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem. 1992 Dec 25;267(36):25934–25938. [PubMed] [Google Scholar]
  14. Lim H., Dey S. K. Prostaglandin E2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. Endocrinology. 1997 Nov;138(11):4599–4606. doi: 10.1210/endo.138.11.5528. [DOI] [PubMed] [Google Scholar]
  15. Lo C. J., Cryer H. G., Fu M., Lo F. R. Regulation of macrophage eicosanoid generation is dependent on nuclear factor kappaB. J Trauma. 1998 Jul;45(1):19–24. doi: 10.1097/00005373-199807000-00004. [DOI] [PubMed] [Google Scholar]
  16. Maier J. A., Hla T., Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem. 1990 Jul 5;265(19):10805–10808. [PubMed] [Google Scholar]
  17. Mitchell J. A., Akarasereenont P., Thiemermann C., Flower R. J., Vane J. R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693–11697. doi: 10.1073/pnas.90.24.11693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  19. Nishigaki N., Negishi M., Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol Pharmacol. 1996 Oct;50(4):1031–1037. [PubMed] [Google Scholar]
  20. O'Banion M. K., Winn V. D., Young D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4888–4892. doi: 10.1073/pnas.89.11.4888. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smith W. L., Marnett L. J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta. 1991 Apr 24;1083(1):1–17. doi: 10.1016/0005-2760(91)90119-3. [DOI] [PubMed] [Google Scholar]
  22. Vane J. R., Botting R. M. The mode of action of anti-inflammatory drugs. Postgrad Med J. 1990;66 (Suppl 4):S2–17. [PubMed] [Google Scholar]
  23. Woodward D. F., Regan J. W., Lake S., Ocklind A. The molecular biology and ocular distribution of prostanoid receptors. Surv Ophthalmol. 1997 Feb;41 (Suppl 2):S15–S21. doi: 10.1016/s0039-6257(97)80003-3. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES